351 related articles for article (PubMed ID: 26004006)
1. Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor.
Chen J; Lu S; Gu W; Peng P; Dong J; Xu F; Yang X; Xiong Z; Yang X
Int J Pharm; 2015 Jul; 490(1-2):219-28. PubMed ID: 26004006
[TBL] [Abstract][Full Text] [Related]
2. Delivery of fluorescent-labeled cyclodextrin by liposomes: role of transferrin modification and phosphatidylcholine composition.
Chen J; Yao J; Ma Z; Peng P; Lu S; Hu Y; Xu F; Yang Y; Yang X
J Liposome Res; 2017 Mar; 27(1):21-31. PubMed ID: 26911560
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
4. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Hong M; Zhu S; Jiang Y; Tang G; Pei Y
J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485
[TBL] [Abstract][Full Text] [Related]
5. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs.
Chen J; Lu WL; Gu W; Lu SS; Chen ZP; Cai BC; Yang XX
Expert Opin Drug Deliv; 2014 Apr; 11(4):565-77. PubMed ID: 24490763
[TBL] [Abstract][Full Text] [Related]
6. Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation.
Jiang Y; Sha X; Zhang W; Fang X
Int J Pharm; 2010 Sep; 397(1-2):116-21. PubMed ID: 20637848
[TBL] [Abstract][Full Text] [Related]
7. Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization.
Vaidya B; Vyas SP
J Drug Target; 2012 May; 20(4):372-80. PubMed ID: 22339366
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio.
Chen J; Hu RR; Yang XX; Gu W; Tian R; Gong F; Luo L; Fang F; Chen ZP; Cai BC
Cancer Chemother Pharmacol; 2013 Oct; 72(4):925-9. PubMed ID: 23934323
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome.
Wang X; Deng L; Cai L; Zhang X; Zheng H; Deng C; Duan X; Zhao X; Wei Y; Chen L
J Pharm Sci; 2011 Aug; 100(8):3357-3364. PubMed ID: 21387317
[TBL] [Abstract][Full Text] [Related]
10. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
11. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Chang Q; Geng R; Wang S; Qu D; Kong X
Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation.
Jiang Y; Jiang X; Law K; Chen Y; Gu J; Zhang W; Xin H; Sha X; Fang X
Int J Pharm; 2011 Aug; 415(1-2):252-8. PubMed ID: 21645594
[TBL] [Abstract][Full Text] [Related]
13. 9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.
Dadashzadeh S; Derakhshandeh K; Shirazi FH
Anticancer Drugs; 2008 Sep; 19(8):805-11. PubMed ID: 18690092
[TBL] [Abstract][Full Text] [Related]
14. Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation.
Lian X; Dong J; Zhang J; Teng Y; Lin Q; Fu Y; Gong T
Int J Pharm; 2014 Dec; 477(1-2):399-407. PubMed ID: 25445521
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes.
Zhang LJ; Xing B; Wu J; Xu B; Fang XL
Pulm Pharmacol Ther; 2008; 21(1):239-46. PubMed ID: 17561423
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-beta-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery.
McCormack B; Gregoriadis G
Biochim Biophys Acta; 1996 Dec; 1291(3):237-44. PubMed ID: 8980638
[TBL] [Abstract][Full Text] [Related]
17. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
Lu JL; Wang JC; Zhao SX; Liu XY; Zhao H; Zhang X; Zhou SF; Zhang Q
Eur J Pharm Biopharm; 2008 Aug; 69(3):899-907. PubMed ID: 18434109
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
19. Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection.
Chen J; Cai B; Ping Q; Liu M; Guo J
Drug Dev Ind Pharm; 2008 Aug; 34(8):853-9. PubMed ID: 18686092
[TBL] [Abstract][Full Text] [Related]
20. Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin.
Chen J; Ping QN; Guo JX; Chu XZ; Song MM
Drug Dev Ind Pharm; 2006 Jul; 32(6):719-26. PubMed ID: 16885127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
